De-Risking Regulatory Submissions: Lessons from 202 FDA CRLs
Most applications that receive a Complete Response Letter do not fail on science. This briefing reviews 202 CRLs issued by the FDA and shows that the dominant failure domain is operational: manufacturing, product characterisation and device usability. It ranks the specific deficiencies the agency cites, and sets out who inside a sponsor owns each one.
What this report answers
- What actually causes the FDA to issue a Complete Response Letter?
- Is the biggest rejection risk in the clinical data package or in manufacturing?
- Which specific CMC deficiencies does the FDA cite most often, and in what order?
- Do failure patterns differ between biologics, small molecules and combination products?
- How much weight does the FDA put on human factors and device usability?
- Which leadership roles own each category of submission risk before filing?
202
Complete Response Letters released by the FDA and read individually for this analysis, each one coded by deficiency type before any rate was calculated.
74%
the share of those letters ProGen Search's analysis found citing at least one major deficiency in Chemistry, Manufacturing and Controls - the figure the briefing builds its argument about execution risk on.
What the analysis establishes
The three domains where submissions fail
The analysis sorts every deficiency cited across the 202 letters into three domains: manufacturing and product quality, clinical evidence and strategy, and device and user interface integration. Each domain is given an incidence rate across the sample, and the briefing establishes which of the three carries the most rejection risk and which is most expensive to remediate once a letter has been issued.
A ranked table of the deficiencies the FDA actually cites
Rather than describing rejection risk in general terms, the briefing tabulates the individual deficiencies inside each domain, ranked by how often they appear across the sample. Ten CMC deficiency types, ten clinical types and five device types are listed with their incidence and an illustrative verbatim line from a real CRL, so the agency's own wording sits next to each pattern.
Where the execution gap opens
The deep-dive chapter works through the largest failure modes in turn: facility and inspection status, product characterisation, and demonstrated process control. It establishes how far into a review cycle each type of gap is typically discovered, and why some of them cannot be closed by supplying more data once the letter has arrived.
Failure patterns are not the same across modalities
The sample is segmented by therapeutic modality - biologics and biosimilars, small molecules, and combination products - with a share of the analysed letters given for each. Every segment has a different top failure reason and a different secondary challenge, which is the part most sponsors get wrong when they benchmark their own risk against industry averages.
What the FDA writes when it says no
Throughout, the analysis quotes the agency directly rather than paraphrasing it. The recurring formulations matter: the briefing shows which phrases signal a gap that can be answered with existing data and which signal a requirement for new studies, new batches or a new inspection outcome.
Who owns each risk before filing
The final chapter converts the statistics into role-specific action plans for the Head of CMC and Technical Operations, the VP of Regulatory Affairs, the Chief Medical Officer and the Head of Quality. Each checklist item is tied back to the incidence figure that justifies it, and to the point in the development timeline at which acting on it is still cheap.
How it was built
A systematic review of the 202 Complete Response Letters released by the U.S. Food and Drug Administration, synthesised from the public record. Every letter was read and its deficiencies coded into categories, so a single letter can contribute to several. Incidence is reported as the share of the 202 letters citing a category at least once, not as a share of total deficiencies. Modality shares and the sub-segment rates are ProGen Search's own classification of the sample, and are labelled as approximate in the report where the coding involved judgement.
Written for sponsors preparing an NDA, BLA or 505(b)(2) submission, and for the CMC, regulatory, clinical and quality leaders who own the risk inside them. Also used by investors running diligence on an asset approaching filing.
Contents
- Executive Summary: The Execution Imperative
- The Quantitative Landscape of Submission Deficiencies
- Deep Dive Analysis: Primary Failure Modes
- Modality-Specific Failure Patterns
- Strategic Imperatives and Role-Specific Action Plans
Regulators referenced
FDA, U.S. Food and Drug Administration
The full 17-page briefing is free. Tell us where to send it and it downloads immediately.